{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:20:54Z","timestamp":1790036454600,"version":"4.0.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2018,2,14]],"date-time":"2018-02-14T00:00:00Z","timestamp":1518566400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Health and Labor Sciences Research Grants for research on intractable diseases from the Ministry of Health, Labour, and Welfare of Japan"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Jpn J Ophthalmol"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1007\/s10384-018-0561-1","type":"journal-article","created":{"date-parts":[[2018,2,14]],"date-time":"2018-02-14T10:38:11Z","timestamp":1518604691000},"page":"101-108","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Diagnosis and treatment of anti-myelin oligodendrocyte glycoprotein antibody positive optic neuritis"],"prefix":"10.1007","volume":"62","author":[{"given":"Takeshi","family":"Kezuka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,2,14]]},"reference":[{"key":"561_CR1","doi-asserted-by":"publisher","first-page":"294046","DOI":"10.1155\/2011\/294046","volume":"2011","author":"T Kezuka","year":"2011","unstructured":"Kezuka T, Usui Y, Goto H. Analysis of the pathogenesis of experimental autoimmune optic neuritis. J Biomed Biotechnol. 2011;2011:294046.","journal-title":"J Biomed Biotechnol"},{"issue":"45","key":"561_CR2","doi-asserted-by":"publisher","first-page":"4060","DOI":"10.1167\/iovs.04-0554","volume":"45","author":"H Shao","year":"2004","unstructured":"Shao H, Huang Z, Sun SL, Kaplan HJ, Sun D. Myelin\/oligodendrocyte glycoprotein-specific T-cells induce severe optic neuritis in the C57BL\/6 mouse. Invest Ophthalmol Vis Sci. 2004;45(45):4060\u20135.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"561_CR3","first-page":"443","volume":"130","author":"C Linington","year":"1988","unstructured":"Linington C, Bradl M, Lassmann H, Brunner C, Vass K. Augmentation of demyelination in rat acute allergic encephalomyelitis by circulating mouse monoclonal antibodies directed against a myelin\/oligodendrocyte glycoprotein. Am J Pathol. 1988;130:443\u201354.","journal-title":"Am J Pathol"},{"key":"561_CR4","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1111\/j.1471-4159.1990.tb04173.x","volume":"55","author":"N Kerlero Rosbo de","year":"1990","unstructured":"de Kerlero Rosbo N, Honegger P, Lassmann H, Matthieu JM. Demyelination induced in aggregating brain cell cultures by a monoclonal antibody against myelin\/ oligodendrocyte glycoprotein. J Neurochem. 1990;55:583\u20137.","journal-title":"J Neurochem"},{"issue":"53","key":"561_CR5","doi-asserted-by":"publisher","first-page":"6964","DOI":"10.1167\/iovs.12-10559","volume":"9","author":"Y Matsunaga","year":"2012","unstructured":"Matsunaga Y, Kezuka T, An X, Fujita K, Matsuyama N, Matsuda R, et al. Visual functional and histopathological correlation in experimental autoimmune optic neuritis. Invest Ophthalmol Vis Sci. 2012;9(53):6964\u201371.","journal-title":"Invest Ophthalmol Vis Sci."},{"issue":"103","key":"561_CR6","doi-asserted-by":"publisher","first-page":"2280","DOI":"10.1073\/pnas.0510672103","volume":"14","author":"PH Lalive","year":"2006","unstructured":"Lalive PH, Menge T, Delarasse C, Della Gaspera B, Pham-Dinh D, Villoslada P, et al. Antibodies to native myelin oligodendrocyte glycoprotein are serologic markers of early inflammation in multiple sclerosis. Proc Natl Acad Sci USA. 2006;14(103):2280\u20135.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"27","key":"561_CR7","doi-asserted-by":"publisher","first-page":"13992","DOI":"10.1073\/pnas.0504979102","volume":"102","author":"CB Marta","year":"2005","unstructured":"Marta CB, Oliver AR, Sweet RA, Pfeiffer SE, Ruddle NH. Pathogenic myelin oligodendrocyte glycoprotein antibodies recognize glycosylated epitopes and perturb oligodendrocyte physiology. Proc Natl Acad Sci USA. 2005;102(27):13992\u20137.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"12","key":"561_CR8","doi-asserted-by":"publisher","first-page":"19057","DOI":"10.1073\/pnas.0607242103","volume":"103","author":"D Zhou","year":"2006","unstructured":"Zhou D, Srivastava R, Nessler S, Grummel V, Sommer N, Br\u00fcck W, et al. Identification of a pathogenic antibody response to native myelin oligodendrocyte glycoprotein in multiple sclerosis. Proc Natl Acad Sci USA. 2006;103(12):19057\u201362.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6","key":"561_CR9","doi-asserted-by":"publisher","first-page":"e163","DOI":"10.1212\/NXI.0000000000000163","volume":"2","author":"SM Kim","year":"2015","unstructured":"Kim SM, Woodhall MR, Kim JS, Kim SJ, Park KS, Vincent A, et al. Antibodies to MOG in adults with inflammatory demyelinating disease of the CNS. Neurol Neuroimmunol Neuroinflamm. 2015;2(6):e163.","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"561_CR10","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1136\/jnnp-2013-306411","volume":"85","author":"Y Hacohen","year":"2014","unstructured":"Hacohen Y, Absoud M, Woodhall M, Cummins C, De Goede CG, Hemingway C, et al. Autoantibody biomarkers in childhood-acquired demyelinating syndromes: results from a national surveillance cohort. J Neurol Neurosurg Psychiatr. 2014;85:456\u201361.","journal-title":"J Neurol Neurosurg Psychiatr"},{"issue":"265\u201372","key":"561_CR11","first-page":"7","volume":"86","author":"M Baumann","year":"2015","unstructured":"Baumann M, Sahin K, Lechner C, Hennes EM, Schanda K, Mader S, et al. Clinical and neuroradiological differences of paediatric acute disseminating encephalomyelitis with and without antibodies to the myelin oligodendrocyte glycoprotein. J Neurol Neurosurg Psychiatr. 2015;86(265\u201372):7.","journal-title":"J Neurol Neurosurg Psychiatr"},{"issue":"77","key":"561_CR12","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1212\/WNL.0b013e318228c0b1","volume":"9","author":"AK Pr\u00f6bstel","year":"2011","unstructured":"Pr\u00f6bstel AK, Dornmair K, Bittner R, Sperl P, Jenne D, Magalhaes S, et al. Antibodies to MOG are transient in childhood acute disseminated encephalomyelitis. Neurology. 2011;9(77):580\u20138.","journal-title":"Neurology"},{"issue":"289","key":"561_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jneuroim.2015.10.002","volume":"15","author":"P Horellou","year":"2015","unstructured":"Horellou P, Wang M, Keo V, Chr\u00e9tien P, Serguera C, Waters P, et al. Increased interleukin-6 correlates with myelin oligodendrocyte glycoprotein antibodies in pediatric monophasic demyelinating diseases and multiple sclerosis. J Neuroimmunol. 2015;15(289):1\u20137.","journal-title":"J Neuroimmunol"},{"key":"561_CR14","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1001\/archneurol.2011.2956","volume":"69","author":"K Rostasy","year":"2012","unstructured":"Rostasy K, Mader S, Schanda K, Huppke P, G\u00e4rtner J, Kraus V, et al. Anti\u2013myelin oligodendrocyte glycoprotein antibodies in pediatric patients with optic neuritis. Arch Neurol. 2012;69:752\u20136.","journal-title":"Arch Neurol"},{"issue":"85","key":"561_CR15","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","volume":"14","author":"DM Wingerchuk","year":"2015","unstructured":"Wingerchuk DM, Banwell B, Bennett JL, Cabre P, Carroll W, Chitnis T, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015;14(85):177\u201389.","journal-title":"Neurology"},{"key":"561_CR16","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s12974-015-0256-1","volume":"12","author":"AK Pr\u00f6bstel","year":"2015","unstructured":"Pr\u00f6bstel AK, Rudolf G, Dornmair K, Collongues N, Chanson JB, Sanderson NS, et al. Anti-MOG antibodies are present in a subgroup of patients with a neuromyelitis optica phenotype. J Neuroinflamm. 2015;12:46\u201353.","journal-title":"J Neuroinflamm"},{"key":"561_CR17","first-page":"1688","volume":"71","author":"T Goseki","year":"2017","unstructured":"Goseki T. Refractory optic neuritis nation survey in Japan. Rinsho Ganka (in Japanese). 2017;71:1688\u201390.","journal-title":"Rinsho Ganka (in Japanese)"},{"key":"561_CR18","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1097\/WNO.0b013e31823c9b6c","volume":"32","author":"T Kezuka","year":"2012","unstructured":"Kezuka T, Usui Y, Yamakawa N, Matsunaga Y, Matsuda R, Masuda M, et al. Relationship between NMO-antibody and anti-MOG antibody in optic neuritis. J Neuro-Ophthalmol. 2012;32:107\u201310.","journal-title":"J Neuro-Ophthalmol"},{"key":"561_CR19","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1212\/WNL.0000000000000101","volume":"82","author":"DK Sato","year":"2014","unstructured":"Sato DK, Callegaro D, Lana-Peixoto MA, Waters PJ, de Haidar Jorge FM, Takahashi T, et al. Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders. Neurology. 2014;82:474\u201381.","journal-title":"Neurology"},{"key":"561_CR20","doi-asserted-by":"publisher","first-page":"213","DOI":"10.3109\/01658107.2015.1072726","volume":"39","author":"R Matsuda","year":"2015","unstructured":"Matsuda R, Kezuka T, Umazume A, Okunuki Y, Goto H, Tanaka K. Clinical profile of anti-myelin oligodendrocyte glycoprotein antibody seropositive cases of optic neuritis. Neuro-Ophthalmol. 2015;39:213\u20139.","journal-title":"Neuro-Ophthalmol"},{"issue":"2","key":"561_CR21","doi-asserted-by":"publisher","first-page":"e89","DOI":"10.1212\/NXI.0000000000000089","volume":"19","author":"P Waters","year":"2015","unstructured":"Waters P, Woodhall M, O\u2019Connor KC, Reindl M, Lang B, Sato DK, et al. MOG cell-based assay detects non-MS patients with inflammatory neurologic disease. Neurol Neuroimmunol Neuroinflamm. 2015;19(2):e89.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"561_CR22","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1186\/s12974-016-0720-6","volume":"13","author":"F Pache","year":"2016","unstructured":"Pache F, Zimmermann H, Mikolajczak J, Schumacher S, Lacheta A, Oertel FC, et al. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 4: afferent visual system damage after optic neuritis in MOG-IgG-seropositive versus AQP4-IgG-seropositive patients. J Neuroinflamm. 2016;13:282.","journal-title":"J Neuroinflamm"},{"key":"561_CR23","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1212\/WNL.0000000000000636","volume":"83","author":"T Kezuka","year":"2014","unstructured":"Kezuka T, Tanaka K, Matsunaga Y, Goto H. Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders. Neurology. 2014;83:475.","journal-title":"Neurology"},{"key":"561_CR24","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1055\/s-0034-1371179","volume":"45","author":"A Miyauchi","year":"2014","unstructured":"Miyauchi A, Monden Y, Watanabe M, Sugie H, Morita M, Kezuka T, et al. Persistent presence of the anti-myelin oligodendrocyte glycoprotein autoantibody in a pediatric case of acute disseminated encephalomyelitis followed by optic neuritis. Neuropediatrics. 2014;45:196\u20139.","journal-title":"Neuropediatrics"},{"key":"561_CR25","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1136\/jnnp-2014-310206","volume":"87","author":"T Akaishi","year":"2016","unstructured":"Akaishi T, Sato DK, Nakashima I, Takeshita T, Takahashi T, Doi H, et al. MRI and retinal abnormalities in isolated optic neuritis with myelin oligodendrocyte glycoprotein and aquaporin-4 antibodies: a comparative study. J Neurol Neurosurg Psychiatr. 2016;87:446\u20138.","journal-title":"J Neurol Neurosurg Psychiatr"},{"key":"561_CR26","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.jneuroim.2016.02.004","volume":"293","author":"T Akaishi","year":"2016","unstructured":"Akaishi T, Nakashima I, Takeshita T, Mugikura S, Sato DK, Takahashi T, et al. Lesion length of optic neuritis impacts visual prognosis in neuromyelitis optica. J Neuroimmunol. 2016;293:28\u201333.","journal-title":"J Neuroimmunol"},{"key":"561_CR27","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1186\/s12974-016-0718-0","volume":"13","author":"S Jarius","year":"2016","unstructured":"Jarius S, Ruprecht K, Kleiter I, Borisow N, Asgari N, Pitarokoili K. In cooperation with the Neuromyelitis Optica Study Group (NEMOS). MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. J Neuroinflamm. 2016;13:280.","journal-title":"J Neuroinflamm"},{"key":"561_CR28","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1177\/1756285616655264","volume":"9","author":"EH Martinez-Lapiscina","year":"2016","unstructured":"Martinez-Lapiscina EH, Sepulveda M, Torres-Torres R, Alba-Arbalat S, Llufriu S, Blanco Y, et al. Usefulness of optical coherence tomography to distinguish optic neuritis associated with AQP4 or MOG in neuromyelitis optica spectrum disorders. Ther Adv Neurol Disord. 2016;9:436\u201340.","journal-title":"Ther Adv Neurol Disord"},{"key":"561_CR29","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1093\/brain\/awg045","volume":"126 (Pt 2)","author":"D Kidd","year":"2003","unstructured":"Kidd D, Burton B, Plant GT, Graham EM. Chronic relapsing inflammatory optic neuropathy (CRION). Brain. 2003;126 (Pt 2):276\u201384.","journal-title":"Brain"},{"key":"561_CR30","doi-asserted-by":"publisher","first-page":"e131","DOI":"10.1212\/NXI.0000000000000131","volume":"2","author":"K Chalmoukou","year":"2015","unstructured":"Chalmoukou K, Alexopoulos H, Akrivou S, Stathopoulos P, Reindl M, Dalakas MC. Anti-MOG antibodies are frequently associated with steroid-sensitive recurrent optic neuritis. Neurol Neuroimmunol Neuroinflamm. 2015;2:e131.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"561_CR31","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1001\/archopht.1991.01080120057025","volume":"109","author":"The clinical profile of optic neuritis","year":"1991","unstructured":"The clinical profile of optic neuritis. Experience of the optic neuritis treatment trial. Optic Neuritis Study Group. Arch Ophthalmol. 1991;109:1673\u20138.","journal-title":"Arch Ophthalmol"},{"key":"561_CR32","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/S0021-5155(98)00072-0","volume":"43","author":"M Wakakura","year":"1999","unstructured":"Wakakura M, Minei-Higa R, Oono S, Matsui Y, Tabuchi A, Kani K, et al. Baseline features of idiopathic optic neuritis as determined by a multicenter treatment trial in Japan. Optic Neuritis Treatment Trial Multicenter Cooperative Research Group (ONMRG). Jpn J Ophthalmol. 1999;43:127\u201332.","journal-title":"Jpn J Ophthalmol"}],"container-title":["Japanese Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10384-018-0561-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10384-018-0561-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10384-018-0561-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,2,14]],"date-time":"2019-02-14T00:44:13Z","timestamp":1550105053000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10384-018-0561-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,14]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["561"],"URL":"https:\/\/doi.org\/10.1007\/s10384-018-0561-1","relation":{},"ISSN":["0021-5155","1613-2246"],"issn-type":[{"value":"0021-5155","type":"print"},{"value":"1613-2246","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,14]]},"assertion":[{"value":"30 June 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"T. Kezuka, None; H. Ishikawa, None.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}